Kisspeptin-10

What it is

Kisspeptin-10 (KP-10, CAS 374675-21-5) is the C-terminal 45–54 fragment of the KISS1 gene product, sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂. The C-terminal amide is what defines the RFamide family and is required for bioactivity — incomplete amidation is a genuine quality problem with this compound, so sourcing matters more here than with most. It binds KISS1R (GPR54) on hypothalamic GnRH neurons, triggering GnRH release, which drives LH and FSH from the pituitary and downstream sex hormone production. The action is at the top of the hypothalamic-pituitary-gonadal axis, not at the gonads.

LH and FSH rise following administration, with downstream sex hormone production following. Because the compound works through the hormonal axis rather than through arousal pathways directly, the response builds over a course rather than arriving on a single occasion. Human imaging studies have separately reported changes in how the brain processes sexual and emotional stimuli. The individual response depends on baseline hormonal status, which is one reason practitioner supervision matters.

• Stimulation of LH and FSH release in healthy human subjects
• Activation of the hypothalamic-pituitary-gonadal axis upstream of the gonads
• Modulation of sexual and emotional brain processing in human functional imaging studies
• Clinical research interest in hypothalamic dysfunction and reproductive disorders
• Studied as a diagnostic probe of hypothalamic function as well as a therapeutic candidate

Who it's for

• Low libido where the hormonal axis, rather than arousal itself, is the suspected limiting factor
• Clients working with a practitioner on hormonal support who want an upstream mechanism
• Protocols where hormone markers can be measured before and during use

• Pregnancy or breastfeeding
• Hormone-sensitive cancers — this compound drives sex hormone production
• Anyone undergoing fertility treatment without their treating clinician involved
• Unsupervised use — this modulates a hormonal axis and warrants practitioner oversight
• Clients wanting an on-demand effect before a specific occasion — that is not how it works

Protocol guidance

Contraindications & cautions

• This modulates a hormonal axis — it is not a libido compound in the same sense as PT-141, and should be practitioner-supervised
• Contraindicated in pregnancy, breastfeeding, and hormone-sensitive cancers
• Anyone in fertility treatment must involve their clinician before use — this compound acts directly on the axis being treated
• Product quality matters unusually here: bioactivity depends on the C-terminal amide, and incomplete amidation is a known issue with this peptide
• Not a faster or stronger PT-141 — the mechanisms and timescales are different

Pairs well with

Research